Navigation Links
Raptor Pharmaceuticals Provides Update of Product Programs
Date:9/13/2007

Poster at Upcoming International Liver Cancer Conference

Status of Ongoing Programs

Regulatory Consulting Firm Retained

NOVATO, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP.OB) announced today that Dr. Todd Zankel, the Company's Chief Scientific Officer, will present a poster detailing promising preclinical results from two preclinical studies of its HepTide(TM) liver targeting program at the International Liver Cancer ("ILCA") Conference, to be held October 5-7, 2007 in Barcelona, Spain.

Dr. Zankel's presentation will include an update on Raptor's liver targeting platform based on human receptor-associated protein ("RAP"). For more information on ILCA and the 2007 ILCA Conference, please visit http://www.ilca-online.org. A synopsis of the poster will be available in the investor relations section of Raptor's website at http://www.raptorpharma.com shortly after Dr. Zankel presents at the conference.

Current Program Updates:

Investigational New Drug Application ("IND")-Enabling Studies Initiated for HepTide(TM)

Based on promising results from ongoing preclinical studies of its RAP liver targeting program, Raptor has initiated a pre-IND program for HepTide(TM) (its liver targeting therapeutic conjugate using the RAP targeting platform). The Company's goal is to file an IND for this therapeutic conjugate with the Food and Drug Administration (the "FDA") by the end of the second calendar quarter of 2008. To help execute this plan the Company has retained Regulatory Professionals, Inc., a regulatory consulting firm experienced in working with the FDA in all aspects of regulatory affairs including preclinical and clinical support for pre- and post-approval products, and preparation and submis
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  Decision Resources Group finds that the market for ... billion by 2023 in the United States ... , Italy , Spain ... Japan . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin ... by the launch of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, ...
(Date:8/28/2014)... , Aug. 28, 2014 Levi & ... commenced in the United States District Court for the ... of investors who purchased Galectin Therapeutics Inc. ("Galectin" or ... and July 28, 2014. For more information, ... alleges that during the Class Period the Company violated ...
(Date:8/28/2014)... , Aug. 28, 2014 Nonin Medical, ... leader in noninvasive medical monitoring, today announced that the ... Model 3231 OEM/eHealth finger pulse oximeter for use in ... pulse oximeter plugs into a telemedicine hub or kiosk ... pulse rate in pediatric to adult patients. The Model ...
Breaking Medicine Technology:The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... to Produce Therapeutic Proteins at Tumor,Site, ARLINGTON ... surgeons have delivered cancer fighting proteins through,skin flaps ... 79 percent reduction,in tumor volume, according to a ... Surgery(R), the official medical journal of the American,Society ...
... today announced the submission of a supplemental New ... Administration (FDA) for SEROQUEL XR(TM),(quetiapine fumarate) Extended-Release Tablets ... disorder (GAD), including maintenance of,antianxiety effect. It is ... an,atypical antipsychotic medicine in GAD. The submission is ...
Cached Medicine Technology:Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8
(Date:8/28/2014)... 2014 Valero Renewable Fuels Company, LLC, ... VLO), and the Ports of Indiana hosted Lt. Gov. ... at a Port Appreciation and Welcome Celebration commemorating the ... , “The opening of Valero’s ethanol facility at the ... development win for the State of Indiana,” Ellspermann said. ...
(Date:8/28/2014)... HealthDay Reporter THURSDAY, Aug. ... electrical currents through the scalp to a specific network of ... day. In a small study of healthy young adults, ... networks involved in memory. That, in turn, boosted participants, performance ... the brain stimulation. During TMS, an electromagnetic coil is ...
(Date:8/28/2014)... IL (PRWEB) August 28, 2014 Data ... Supplement shows that while most hospitals utilize a basic ... health care information technology is still a challenge. ... the August issue of Health Affairs , and ... Forum’s Health Care Data Center, as well as Chantal ...
(Date:8/28/2014)... is hurting reproduction of the endangered Devils Hole pupfish, threatening ... few as 35 individuals, new research by the University of ... that geothermal water on a small shelf near the surface ... pupfish live is heating up as a result of climate ... , The hotter water, which now reaches more than ...
(Date:8/28/2014)... 28, 2014 Dr. Paul Kovatis is being ... the U.S. military for his efforts to treat many wounded ... Warriors Foundation and several other military organizations. Dr. Kovatis’ ... in WWII. Having five members of his immediate family ... Cemetery, it’s no wonder Dr. Kovatis is so dedicated to ...
Breaking Medicine News(10 mins):Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3Health News:Electrical Pulses to Scalp May Boost Memory: Study 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 3Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 3Health News:Climate change puts endangered Devils Hole pupfish at risk of extinction 2Health News:Climate change puts endangered Devils Hole pupfish at risk of extinction 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis 2
... survey reveals that 61% of Australians are not aware of the ... the Salvation Army survey, binge drinking was "worryingly high" among teenage ... 41 % of the18 to 24-year-olds confessed to take not less ... ,"What is of such concern is that people don't know ...
... New York: An investigation into the degree of consequence type ... the condition before 50 years//, led to the finding that ... say Swedish researchers. ,The status of type ... measured with the presence of biological identification in the blood ...
... well known that the output of nerve cells is the ... is still unclear about how widely separated regions of the ... complex activity. A new study by neuroscientists at the University ... Francisco (UCSF) is getting to resolve this mystery. ...
... the degree of hangover one might experience, after a night ... delved into this arena, and studied the connection between the ... by being hangover less as compared to the ones with ... a hangover, characterized by an unbearable headache, nausea, dry mouth ...
... type 1 Diabetes was admitted to the Clinical Research Center ... // Four days later the North Shore suburban girl was ... body and ready to spend a few days at the ... to do well, her insulin was reduced day by day. ...
... would benefit a lot if they were given albumin ... in London and experts in Kenya have developed this ... with malaria. ,In initial studies less ... new treatment died, researchers said. "The observation is that ...
Cached Medicine News:Health News:The need for cancer warnings on alcohol packaging 2Health News:Slow brain waves integral in coordination of complex activity 2Health News:Molecular Medicine And Diabetes 2Health News:Molecular Medicine And Diabetes 3Health News:Molecular Medicine And Diabetes 4Health News:Molecular Medicine And Diabetes 5Health News:Molecular Medicine And Diabetes 6Health News:Molecular Medicine And Diabetes 7
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Pe-Plus offers an additional clinical option for replacing the acetabulum....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Medicine Products: